Chimeric antigen receptor T cell therapy in oncology – Pipeline at a glance: Analysis of the ClinicalTrials.gov database

•We forecast 900 trials in CAR T-cell therapy during 2020–2025.•47 clinical trials use allogeneic products, and we expect this to double by 2025.•48 trials are using dual targeted CAR T-cells aiming to minimize antigen escape.•Phase 3 trials are registered for CD19, BCMA, CD123, and CLL1.•Anti-BCMA...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Critical reviews in oncology/hematology 2021-03, Vol.159, p.103239-103239, Article 103239
Hauptverfasser:	Moreno-Cortes, E., Forero-Forero, J.V., Lengerke-Diaz, P.A., Castro, J.E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adoptive immunotherapy Antigens, CD19 Cell- and Tissue-Based Therapy Chimeric antigen receptor Clinical Trials as Topic Databases, Factual Humans Immunotherapy, Adoptive Neoplasm antigens Neoplasms - therapy Receptors, Antigen, T-Cell - genetics Receptors, Chimeric Antigen - genetics Trends
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!